PMID- 28983584
OWN - NLM
STAT- MEDLINE
DCOM- 20180625
LR  - 20191210
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Print)
IS  - 1791-2997 (Linking)
VI  - 16
IP  - 6
DP  - 2017 Dec
TI  - Na+/K+‑ATPase DR region‑specific antibody protects U251 cells against hypoxia 
      reperfusion‑induced injury via the PI3K/AKT and ERK pathways.
PG  - 7901-7906
LID - 10.3892/mmr.2017.7622 [doi]
AB  - Cerebral ischemia is a condition in which there is insufficient blood flow to the 
      brain to meet metabolic demand. This leads to poor oxygen supply or cerebral 
      hypoxia and to the death of brain tissue or cerebral infarction/ischemic stroke. 
      In the present study, an Na+/K+‑ATPase (NKA) DR region‑specific antibody (DRSAb) 
      was established and purified and it was demonstrated that DRSAb induced a 
      protective effect on human astrocytes (U251) via the phosphoinositide 3‑kinase 
      (PI3K)/AKT and extracellular signal‑regulated protein kinase (ERK) signaling 
      pathways. The binding of DRSAb on NKA was revealed using flow cytometry. High 
      signals were detected on U251 cells incubated with DRSAb, but not with control 
      sera or BSA. The viability of the hypoxia/reperfusion (H/R)‑treated cells was 
      markedly increased by DRSAb administration of 0.3‑0.5 microM. The optimal 
      concentration of DRSAb was 0.4 microM for attenuation of the injury induced by H/R. 
      The administration of 0.4 microM DRSAb markedly reduced the number of apoptotic cells 
      compared with control sera. The application of PD98059, an ERK inhibitor, and 
      LY‑294002, an AKT inhibitor, attenuated the protective effect induced by DRSAb in 
      the U251 cells subjected to H/R. Furthermore, the application of LY294002 prior 
      to incubation with DRSAb eliminated the activation of ERK1/2, whereas the use of 
      PD98059 failed to attenuate the effect of DRSAb on PI3K/AKT activation. These 
      results indicated that the protective effects of DRSAb against H/R injury in U251 
      cells occurred via stimulation of the PI3K/AKT and ERK signaling pathways.
FAU - Gong, Huilin
AU  - Gong H
AD  - Department of Pathology, The First Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, Shaanxi 710061, P.R. China.
FAU - Lu, Pengbiao
AU  - Lu P
AD  - Department of Oncological and Thoracic Surgery, Hanzhong People's Hospital, 
      Hanzhong, Shaanxi 723000, P.R. China.
FAU - Zhang, Jiangwei
AU  - Zhang J
AD  - Hospital of Nephrology, The First Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, Shaanxi 710061, P.R. China.
FAU - Li, Dandong
AU  - Li D
AD  - Department of Neurosurgery, The First Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, Shaanxi 710061, P.R. China.
FAU - Zheng, Jin
AU  - Zheng J
AD  - Hospital of Nephrology, The First Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, Shaanxi 710061, P.R. China.
FAU - Song, Jinning
AU  - Song J
AD  - Department of Neurosurgery, The First Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, Shaanxi 710061, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20170926
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (Antibodies, Monoclonal)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
RN  - EC 7.2.2.13 (Sodium-Potassium-Exchanging ATPase)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/*pharmacology
MH  - Apoptosis/drug effects
MH  - Cell Hypoxia/drug effects
MH  - Cell Line
MH  - Cell Survival/drug effects
MH  - Disease Models, Animal
MH  - Extracellular Signal-Regulated MAP Kinases/*metabolism
MH  - MAP Kinase Signaling System/drug effects
MH  - Male
MH  - Phosphatidylinositol 3-Kinases/*metabolism
MH  - Proto-Oncogene Proteins c-akt/*metabolism
MH  - Rats
MH  - Reperfusion Injury/drug therapy/*metabolism/pathology
MH  - Signal Transduction/*drug effects
MH  - Sodium-Potassium-Exchanging ATPase/*antagonists & inhibitors/*metabolism
PMC - PMC5779871
EDAT- 2017/10/07 06:00
MHDA- 2018/06/26 06:00
PMCR- 2017/09/26
CRDT- 2017/10/07 06:00
PHST- 2015/01/22 00:00 [received]
PHST- 2017/12/28 00:00 [accepted]
PHST- 2017/10/07 06:00 [pubmed]
PHST- 2018/06/26 06:00 [medline]
PHST- 2017/10/07 06:00 [entrez]
PHST- 2017/09/26 00:00 [pmc-release]
AID - mmr-16-06-7901 [pii]
AID - 10.3892/mmr.2017.7622 [doi]
PST - ppublish
SO  - Mol Med Rep. 2017 Dec;16(6):7901-7906. doi: 10.3892/mmr.2017.7622. Epub 2017 Sep 
      26.